IPIX Stock Chart & Stats
<$0.01
$0.00(0.00%)
At close: 4:00 PM EDT
<$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume117.50K
Average Volume (3M)N/A
Market Cap
$161.18K
Enterprise Value-$637.50K
Total Cash (Recent Filing)$864.00K
Total Debt (Recent Filing)$238.00K
Price to Earnings (P/E)―
Beta626.79
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding532,947,450
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)4.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.67
Enterprise Value/Market Cap-3.96
Enterprise Value/Revenue106.25
Enterprise Value/Gross Profit1.70
Enterprise Value/Ebitda0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Innovation Pharmaceuticals News
IPIX FAQ
What was Innovation Pharmaceuticals Inc’s price range in the past 12 months?
Innovation Pharmaceuticals Inc lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Innovation Pharmaceuticals Inc’s market cap?
Innovation Pharmaceuticals Inc’s market cap is $161.18K.
When is Innovation Pharmaceuticals Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Innovation Pharmaceuticals Inc’s earnings last quarter?
Innovation Pharmaceuticals Inc released its earnings results on May 10, 2018. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.02.
Is Innovation Pharmaceuticals Inc overvalued?
According to Wall Street analysts Innovation Pharmaceuticals Inc’s price is currently Overvalued.
Does Innovation Pharmaceuticals Inc pay dividends?
Innovation Pharmaceuticals Inc does not currently pay dividends.
What is Innovation Pharmaceuticals Inc’s EPS estimate?
Innovation Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Innovation Pharmaceuticals Inc have?
Innovation Pharmaceuticals Inc has 532,947,450 shares outstanding.
What happened to Innovation Pharmaceuticals Inc’s price movement after its last earnings report?
Innovation Pharmaceuticals Inc reported an EPS of -$0.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Innovation Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in IPIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies. Its pipeline targets a range of medical areas, including inflammatory diseases, cancer, dermatology, and infectious conditions. The company's lead drug candidate, Brilacidin, is currently in development for treating oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. Furthermore, Innovation Pharmaceuticals is advancing Kevetrin, an anti-cancer compound being investigated for ovarian cancer. The company holds a license agreement with Alfasigma S.p.A. and has a collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. Established in 2005 and headquartered in Wakefield, Massachusetts, the firm operated as Cellceutix Corporation until its name change to Innovation Pharmaceuticals Inc. in June 2017.
Scinai Immunotherapeutics
―
Artelo Biosciences
―
PainReform
―
Dermata Therapeutics
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors